Cite
PET-guided Switch from Immunotherapy to Targeted Therapy in a Metastatic Melanoma Patient: a personalized approach.
MLA
Proietti, I., et al. “PET-Guided Switch from Immunotherapy to Targeted Therapy in a Metastatic Melanoma Patient: A Personalized Approach.” La Clinica Terapeutica, vol. 171, no. 4, July 2020, pp. e283–87. EBSCOhost, https://doi.org/10.7417/CT.2020.2228.
APA
Proietti, I., Filippi, L., Michelini, S., Porta, N., Bernardini, N., Mambrin, A., Tolino, E., Pacini, L., Rosa, P., Calogero, A., Romeo, G., Di Cristofano, C., Petrozza, V., Bagni, O., Skroza, N., & Potenza, C. (2020). PET-guided Switch from Immunotherapy to Targeted Therapy in a Metastatic Melanoma Patient: a personalized approach. La Clinica Terapeutica, 171(4), e283–e287. https://doi.org/10.7417/CT.2020.2228
Chicago
Proietti, I, L Filippi, S Michelini, N Porta, N Bernardini, A Mambrin, E Tolino, et al. 2020. “PET-Guided Switch from Immunotherapy to Targeted Therapy in a Metastatic Melanoma Patient: A Personalized Approach.” La Clinica Terapeutica 171 (4): e283–87. doi:10.7417/CT.2020.2228.